APTX - Aptinyx recommences Phase 2 study of NYX-2925

Aptinyx (APTX) has recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy.Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the U.S.“This study in painful DPN represents the second ongoing Phase 2 study of NYX-2925 in chronic pain, alongside our concurrent study in fibromyalgia, and we expect to read out data from each of these studies in the first half of 2022.” said Norbert Riedel, Ph.D., CEO.Aptinyx pipeline.

For further details see:

Aptinyx recommences Phase 2 study of NYX-2925